• Microbiology and Biotechnology Letters
• /
• v.24 no.4
• /
• pp.472-477
• /
• 1996

Natural human epidermal growth factor (nhEGF) was purified from pregnant human urine by benzoic acid adsorption, DEAE-Sepharose ion exchange, and immunoaffinity chromatography. The purified nhEGF was further separated into four fractions using Bondapak C$_{18}$ HPLC system. Following characterization by Western blot analysis and double immu- nodiffusion, we found that each fraction corresponds to four derivatives of the nhEGF. For biological analysis of nhEGF, we optimized the labeling time and serum concentration for the incorporatioin of 5-bromo-2'-deoxy uridine (BrdU), a non-radioactive alternative for [$^{3}$H]-thymidine uptake, into NIH 3T3 cells. The DNA synthesis of NIH 3T3 cells was gradually increased at the nhEGF concentrations between 0.1 - 10 ng/ml in the Dulbecco's Modified Eagles Medium (DMEM) containing 0.2% Fetal calf serum (FCS). When we assayed the biological activity of four fractions, the activity of the second fraction was superior to that of the others. Based on the results from the HPLC analysis spiked with recombinant human epidermal growth factor (rhEGF) and amino acid sequencing, we concluded that the second fraction was nhEGF and the other three fractions were the derivatives of nhEGF. In addition, the proportion of nhEGF was approximately 46% is compared with that of the other three derivatives.

• Applied Chemistry for Engineering
• /
• v.16 no.2
• /
• pp.226-230
• /
• 2005

Chitosan derivatives, 6-amino-6-deoxychitosan (6A6DC) was successively prepared as a reactive carbohydrate for the stabilization of epidermal growth factor (EGF) by the reactions of chitosan with tosyl chloride, sodium azide, and lithium aluminum tetrahydride. The structure of 6A6DC was confirmed by EA, FT-IR, $^1H-NMR$ and $^{13}C\{^1H\}-NMR$. The degree of substitution (ds) of amino groups in 6A6DC was determined to be 0.7. 6A6DC did not show any cytotoxicity on the normal human dermal fibroblast (NHDF) proliferation at least in the range tested (0.3 g/mL 600 g/mL) and was considered as a suitable material for the stabilization of EGF against proteolytic degradation due to its non-cytotoxicity and high reactivity.

• Biomolecules & Therapeutics
• /
• v.23 no.4
• /
• pp.313-319
• /
• 2015

P7C3 and its derivatives, 1-(3,6-dibromo-9H-carbazol-9-yl)-3-(p-tolylamino)propan-2-ol (1) and N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-hydroxypropyl)-N-(3-methoxyphenyl)-4-methylbenzenesulfonamide (2), were previously reported to increase neurogenesis in rat neural stem cells (NSCs). Although P7C3 is known to increase neurogenesis by protecting newborn neurons, it is not known whether its derivatives also have protective effects to increase neurogenesis. In the current study, we examined how 1 induces neurogenesis. The treatment of 1 in NSCs increased numbers of cells in the absence of epidermal growth factor (EGF) and fibroblast growth factor 2 (FGF2), while not affecting those in the presence of growth factors. Compound 1 did not induce astrocytogenesis during NSC differentiation. 5-Bromo-2'-deoxyuridine (BrdU) pulsing experiments showed that 1 significantly enhanced BrdU-positive neurons. Taken together, our data suggest that 1 promotes neurogenesis by the induction of final cell division during NSC differentiation.